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Background: In steroid-refractory acute severe ulcerative colitis (ASUC), cyclosporine
(CYS) or infliximab (IFX) may be considered as a second-line alternative to avoid
colectomy. There are short-term data reported, but until now, there is no meta-analysis
regarding long-term outcomes of CYS and IFX in patients with ASUC.
Aim: To compare long-term efficacy and safety of CYS and IFX in a meta-analysis.
Methods: Three electronic databases (PubMed, Embase, Cochrane Central Register
of Controlled Trials) were searched for studies which compared CYS vs. IFX in adults
with ASUC. Long-term colectomy-free rate from 1 to 10 years during CYS or IFX therapy
was collected, last updated up to 22nd May 2019. Primary outcome was long-term
colectomy-free rate, secondary outcomes were adverse events (AE), serious adverse
events (SAE), andmortality. Long-term colectomy-free survival and safety measures were
pooled with the random-effect model. Odds ratios (OR) with 95% confidence intervals
(CI) were calculated.
Results: Data from 1,607 patients in 15 trials were extracted. In the first 3 years,
pooled OR for colectomy-free survival was higher with IFX than with CYS (OR =
1.59, 95% CI: 1.11–2.29, p = 0.012; OR = 1.57, 95% CI: 1.14–2.18, p = 0.006;
and OR = 1.75, 95% CI: 1.08–2.84, p = 0.024; at 1, 2, and 3 years, respectively).
However, the significant difference remained undetected from the fourth year of follow-
up and in subgroup of RCTs (OR = 1.35, 95% CI: 0.90–2.01, p = 0.143; OR =
1.41, 95% CI: 0.94–2.12, p = 0.096; and OR = 1.34, 95% CI: 0.89–2.00, p =
0.157; at 1, 2, and 3 years, respectively). No significant difference was detected
regarding adverse events, serious adverse events and mortality between the groups.
The neutral associations proved to be underpowered with trial sequential analysis.
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Conclusion: However observational studies show IFX as a better choice, according
to the RCTs, choosing either CYS or IFX as rescue therapy for ASUC, the long-term
outcomes are not different, although further large RCTs are warranted.
Keywords: steroid-refractory, ulcerative colitis, cyclosporine, infliximab, colectomy, meta-analysis
INTRODUCTION
Ulcerative colitis (UC) is a lifelong inflammatory bowel disease
that causes a continuous mucosal inflammation of the colon
and occurs periodically in patients’ life. Acute severe ulcerative
colitis (ASUC) is a life-threatening condition which requires
hospitalization and occurs in about 25% of patients with UC (1).
ASUC is defined as patients with bloody diarrhea ≥6/day and
any signs of systemic toxicity [pulse > 90/min, temperature >
37.8◦C, hemoglobin < 105 g/l, erythrocyte sedimentation rate
(ESR) > 30 mm/h, or C-reactive protein (CRP) > 30 mg/l] (2).
In the case of ASUC, intravenous (IV) corticosteroids are the
mainstay of first-line treatment, but up to 40% of the cases are
resistant to this therapeutic modality (3). In steroid-refractory
cases, second-line therapy is advised to be introduced to avoid
colectomy. Cyclosporine (CYS) and infliximab (IFX) are widely
used as rescue therapies.
Rationale
CYS is a calcineurin and cytochrome P450 inhibitor
immunosuppressant blocking the transcription of cytokine
genes (interleukin-2 and−4) in activated T cells, thereby
reducing the inflammation in the intestine (4). In the 1990s,
CYS was the first drug introduced as salvage therapy in steroid-
refractory ASUC (5). In general, following 2 mg/kg/day IV CYS,
5 mg/kg oral CYS is recommended for up to 3 months as a
bridge to an immunosuppressive agent [azathioprine (AZA)
or 6-mercaptopurine (6-MP)] (6). Despite the fast response
within 4–7 days and the reliable short-term effectiveness during
CYS therapy, significant side effects may occur (7, 8). A close
drug-level monitoring of CYS is required to avoid opportunistic
infections, renal, vascular and neurological toxicity (9).
In the past 15 years, IFX, a chimeric IgG1 monoclonal
antibody designed to bind tumor necrosis factor-alpha (TNFα)
has become an alternative second-line therapeutic option in
steroid-refractory ASUC (10). Regularly, a standard induction
regimen of 5 mg/kg IFX is used, although recently accelerated
dose intensification with 10 mg/kg IFX is often applied as well
to counteract the increased intestinal clearance of IFX in ASUC
(11). However, there is no data to support the benefit of 10
mg/kg. During IFX-linked immunosuppression, opportunistic
infections, reactivation on latent tuberculosis or hepatitis may
occur; therefore, careful screening is recommended before the
initiation of IFX.
Abbreviations: AE, adverse events; ASUC, acute severe ulcerative colitis; AZA,
azathioprine; CRP, C-reactive protein; CYS, cyclosporine; ESR, erythrocyte
sedimentation rate; IFX, infliximab; IV, intravenous; OR, odds ratio; RCT,
randomized controlled trial; SAE, serious adverse events; TNFα, tumor necrosis
factor-alpha; TSA, trial sequential analysis; UC, ulcerative colitis.
Objectives and Research Question
In the treatment of steroid-refractory ASUC, two randomized
controlled trials (RCTs) demonstrated equal short-term efficacy
and safety of IFX and CYS (CYSIF, CONSTRUCT) (12, 13). These
results were opposed by a previousmeta-analysis of observational
studies, where IFX was associated with significantly higher rates
of treatment response and a lower 12 months colectomy-rate
compared to that with CYS (14). A lately reported network meta-
analysis with benefit-risk analysis also suggested that there is
a rank order of efficacy for colectomy-free rates favoring IFX
over CYS, although the difference between the treatments was
small (15).
Since new studies have been released and long-term survival
data have become available. Therefore, we aimed to summarize
the currently available evidence on the long-term efficacy and
safety of IFX and CYS in steroid-refractory ASUC.
METHODS
Study Design, Participants, Interventions,
and Comparators
This meta-analysis was reported in accordance with the
Preferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) statement (Supplementary Table 1) (16).
The protocol for this study was registered in the International
Prospective Register of Systematic Reviews (PROSPERO) a priori
under number CRD42018115035.
Search Strategy
We searched MEDLINE via PubMed (http://www.ncbi.nlm.nih.
gov/pubmed), Embase (https://www.embase.com) and Cochrane
Central Register of Controlled Trials (CENTRAL) (http://www.
cochranelibrary.com) databases from inception up to 22nd
May 2019.
Our search followed the PICO concept. Studies discussed
a population (P) of patients with steroid-refractory ASUC
who received IFX (I) or CYS (C) as salvage therapy. The
primary outcome (O) was long-term colectomy-free survival
rate, defined as the follow-up period exceeding 12 months
after therapy initiation. Secondary outcomes were adverse
events (AE), serious adverse events (SAE) and mortality.
AE and SAE were categorized in accordance with the
definitions of the International Conference on Harmonization
of Technical Requirements for Registration of Pharmaceuticals
for Human use—Good Clinical Practice (ICH-GCP) consensus
guidelines (17).
The following query combining Medical Subject
Headings (MeSH) and free text terms were used’. (“colitis,
ulcerative”[MeSH Terms] OR (“colitis”[All Fields] AND
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“ulcerative”[All Fields]) OR “ulcerative colitis”[All Fields]
OR (“ulcerative”[All Fields] AND “colitis”[All Fields])) AND
(“infliximab”[MeSH Terms] OR “infliximab”[All Fields]) AND
(“cyclosporine”[MeSH Terms] OR “cyclosporine”[All Fields] OR
“cyclosporin”[All Fields]) AND (“colectomy”[MeSH Terms] OR
“colectomy”[All Fields]). We imposed only “English-language”
and “human” filters on the search.
Study Selection
After the database search, one author (KS) removed the
overlapping records using a reference management software
(EndNote X8, Clarivate Analytics, Philadelphia, PA, USA). Two
investigators (KS and PS) independently screened titles, abstracts,
and full-texts against the predefined eligibility criteria. Consensus
involving a third party (PH) resolved discrepancies in each phase
of selection.
We included any controlled studies (observational or
experimental) that met the following criteria: (a) adult ASUC
patients (aged ≥18 years) being refractory to IV or oral steroid
treatment; (b) CYS and IFX was used as salvage therapy after
3–7 days of steroid treatment; (c) colectomy-free survival rate
was assessed at 12 months or later; and (d) cytomegalovirus
infection was not verified in the patients. There was no restriction
for additional drugs used in UC treatment (e.g., AZA, 6-MP
or methotrexate).
Data Extraction, Quality Assessment
The following data were extracted from each study (Table 1): first
author, year of publication, study type (prospective/retrospective;
randomized/non-randomized), drug regimen, the number of
patients, age, gender distribution, rate of extensive colitis,
concomitant, and maintenance therapy, follow-up period and
the definition of ASUC. Intention-to-treat data were extracted
from RCTs. If numerical data on long-term colectomy-free
survival were not reported (13, 23, 26, 31), we extracted data
from the Kaplan-Meier curves by identifying the values on the
axes “x” and “y” with a software [GetData Graph Digitizer]
according to the method proposed by Guyot et al. (32). Data
collection was accomplished by two authors independently (KS
and PS). Discrepancies were resolved by consensus. In the case
of any disagreement, a third author was involved to resolve
conflicts (PH).
We assessed the risk of bias of observational studies using the
Newcastle-Ottawa scale (NOS) (Table 2) (33). There is a reliable
“star system” that has three broad perspectives to secure a simple
tool for quality assessment: selection and comparability of the
groups, and the ascertainment of the outcome. The quality of
the included RCTs was assessed with the Cochrane Risk of Bias
Tool along seven domains (34). After the assessment, low, high
and unclear risks of bias were indicated with green, red and
yellow symbols.
Data Analysis
Data on colectomy-free survival were extracted with IFX and
CYS. Odds ratios (ORs) were calculated with 95% confidence
intervals using the random effects model with the DerSimonian–
Laird estimation (35). Results of the meta-analysis were displayed
graphically using Forest plots. All analyses were two-tailed and
p< 0.05 was considered as significant.
Subgroup analyses were performed to examine different
effects in a 10 years interval. We carried out subgroup analyses
only for the first 4 years based on the study design because
data from RCTs were lacking for longer follow-up. Heterogeneity
was tested by using the Cochrane’s Q and the I2 statistics,
where I2 = 100% × (Q – df)/Q and represents the magnitude
of the heterogeneity (moderate: 30–60%, substantial: 50–90%,
considerable: 75–100%) (34). All meta-analytical calculations
were performed with Stata 15.1 data analysis and statistical
software (Stata Corp LLC, College Station, TX, USA).
Trial Sequential Analysis
Trial sequential analysis (TSA) was performed to assess the risk
of type-I error and to estimate the required information size
for an adequate statistical power if only RCTs were included
(36). TSA was interpreted with an overall five percent of risk of
type-I error (α = 0.05) and with a power of 80% (Figures 1–3).
Crossing of the constructed cumulative Z-curves (blue) and the
two-sided Z = 1.96 provides a traditionally significant result.
To obtain reliable evidence, crossing of the trial sequential
monitoring boundaries (red) is needed. We conducted TSA
using Trial Sequential Analysis software 0.9 (Copenhagen Trials
Unit, Denmark).
Quality of Evidence
The GRADE system was constructed for the assessment of the
quality of the evidence for the main outcomes in a review (37).
The rating extends from very low to high quality, wherein RCTs
starting from a high, non-randomized studies starting from a
low quality of evidence. After the assessment of study design,
outcomes were tested against five criteria including risk of bias,
inconsistency, indirectness, imprecision and publication bias.
Finally, the overall quality of the evidence for each outcome
was graded as high, moderate, low or very low. Grading was
performed independently by two of the authors (KS and PS) and
disagreements were discussed by involving a third party (AE).
RESULTS
Search Results
A total of 731 records were identified from the databases with our
systematic search strategy (121 records in PubMed, 597 ones in
EMBASE and 13 ones in CENTRAL) (as shown in the PRISMA
flow diagram; Figure 4). Two additional articles were found from
the reference lists of the included studies (19, 38). After the
removal of duplicates, 594 records remained, 565 of which were
excluded by titles and abstracts. The remaining 29 articles were
assessed for eligibility by full-text and further 10 studies were
excluded due to the following reasons: three studies reported
only short-term follow-up data (39–41), one study did not report
on the timing and rate of colectomy (38) and two studies were
uncontrolled (42, 43). In two studies, the number of patients
treated with CYS and IFX was not reported (44, 45), one study
included patients pre-treated with either CYS or IFX (46) and
one study evaluated patients with Crohn’s colitis (47). Nineteen
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TABLE 1 | Study characteristics.
References Drug regimen (number of
patients)
Age (years) Male (%) Extensive
colitis (%)
Concomitant medication Maintenance
therapy
Follow-up
period
Definition of ASUC
RANDOMIZED CONTROLLED TRIALS
Laharie et al. (18)a IFX (55): 5 mg/kg at 0, 2, 6 weeks 36 (26–51)b 28 (51%) 31 (55%) AZA starting at day 7 AZA 7 years Lichtiger score >10 +
Mayo score
CYS (60): 2 mg/kg/day IV for 1
week, then 4mg oral for 3 months
39 (26–50)b 13 (22%) 34 (60%) AZA starting at day 7 AZA
Scimeca et al. (19)a** IFX (17): 5 mg/kg at 0, 2, 6 weeks 39 ± 12c not reported 13 (77%) previous use: AZA/MP,
steroid
AZA 1 year Truelove and Witts score
CYS (13): 5 mg/kg/day oral 39 ± 15c not reported 11 (85%) previous use: AZA/MP,
steroid
AZA
Williams et al. (13)** IFX (135): 5 mg/kg at 0, 2, 6 weeks 39.3 ± 15.5c 89 (66%) 53 (39%) AZA/6-MP started at week
4
AZA/6-MP + IFX 3 years Truelove and Witts + Mayo
score
CYS (135): 2 mg/kg/day IV for 1
week, 5.5 mg/kg oral for 3 months
39.8 ± 15c 81 (60%) 62 (46%) AZA/6-MP started at week
4
AZA/6-MP
OBSERVATIONAL STUDIES
Croft et al. (20)a IFX (37): 5 mg/kg single-dose
infusion
26 (20–43)b 15 (41%) 27 (73%) AZA/6-MP/MTX AZA/6-MP/MTX 1 year Truelove and Witts score
CYS (43): 4 mg/kg (1999–2003), 2
mg/kg (2003–2007), IV for 7 days,
then oral for 3 months
28 (20–37)b 26 (60%) 32 (74%) AZA/6-MP/MTX AZA/6-MP/MTX
Daperno et al. (21)d IFX (6): 5 mg/kg at 0, 2 weeks Not reported Not reported Not reported Steroid AZA 4 years Truelove and Witts score
CYS (15): oral 5 mg/kg/day Not reported Not reported Not reported Steroid AZA
Dean et al. (22)d IFX (19): 5 mg/kg, max. 5 infusion 25 (16–85)b 11 (58%) 10 (53%) AZA AZA/6-MP/MTX 1 year not reported
CYS (19): 2 mg/k/day until
response, then oral
31 (15–56)b 12 (39%) 9 (47%) AZA AZA not reported
Duijvis et al. (23)d IFX (22): 5 mg/kg IV at 0, 2, 6
weeks
35.5 ± 15.4c 14 (64%) 10 (45%) AZA/6-MP/mesalazin IFX 8 years Mayo score
CYS (33): 2 mg/kg/day IV until
response, then oral for 3 months
37.7 ± 13.6c 17 (52%) 17 (52%) AZA/6-MP/mesalazin AZA/6-MP
Kim et al. (24)d IFX (33): 5 mg/kg IV at 0, 2, 6
weeks
44 (15–71)b 25 (76%) 12 (36%) AZA AZA + IFX 3 years According to international
criteria
CYS (10): 2 mg/kg IV until
response, then AZA
56 (22–72)b 3 (30%) 8 (80%) AZA AZA
Mocciaro et al. (25)d IFX (30): 5 mg/kg IV at 0, 2, 6
weeks
37 ± 16.6c 15 (50%) 20 (67%) AZA AZA 3 years Truelove and Witts +
Lichtiger score
CYS (35): 2 mg/kg/day IV, if
responded, switch to oral after 14
days (5 mg/kg)
34.9 ± 13.7c 15 (43%) 29 (83%) AZA AZA
Naves et al. (26)d IFX (30): 5 mg/kg IV at 0, 2, 6
weeks
38 (27–56)b 30 (100%) 21 (70%) AZA/6-MP IFX 6 years Montreal severity score
CYS (20): 2–4 mg/kg 42 (30–50)b 13 (65%) 14 (70%) AZA AZA
Ordás et al. (27)d IFX (131): 5 mg/kg IV at 0, 2, 6
weeks
40 (13–83)b 76 (58%) 91 AZA AZA 5 years According to international
criteria
CYS (377): 2–4 mg/kg, then 5–10
mg/kg oral
36 (9–83)b 217 (58%) 295 NA AZA
(Continued)
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studies remained, but four additional studies were excluded from
the quantitative synthesis because they investigated overlapping
study population (12, 48–50). Thus, 15 studies fulfilled all
inclusion criteria and were included in the meta-analysis.
Characteristics of the Studies Included
The main characteristics of the included studies are listed in
Table 1. The studies were published between 2004 and 2018 and
the follow-up period ranged at least from 1 year to maximum of
10 years. In the quantitative analysis, we used data from three
RCTs (13, 18, 19) and 12 cohort studies (20–31). A total number
of 1,607 patients with steroid-refractory ASUC were included,
879 of which (54.7%) were treated with CYS and the other 728
(45.3%) with IFX. Themost common definitions of ASUCused in
the studies were the Truelove andWitts criteria, theMayo and the
Lichtiger scores (7, 51, 52). Three of the 15 articles were published
only in conference abstract form (19, 29, 31).
In most of the studies, the standard 2 mg/kg/day IV CYS
regimen was applied, oral CYS was used for induction of
remission only in two studies (19, 21). After the oral CYS
bridging, AZAmaintenance therapy was continued in all studies.
Standard 5 mg/kg dose of IFX was administered in multiple IV
infusions (at 0, 2, and 6 weeks) following the induction protocol.
Only two studies reported a single infusion of IFX (20, 30).
In the IFX treatment groups, AZA was the most commonly
administered maintenance drug, albeit recent studies continued
IFX (13, 23, 24, 26, 28). Due to the lack of available safety data
during long-term follow-up in an RCT, the CYSIF trial (18), AE
and SAE results reported in the original study were used in the
meta-analysis (12).
Long-Term Colectomy-Free Survival
Fifteen, eight, five, and one studies reported 1, 3, 5, and 10 years
colectomy-free survival rate. In the first 3 years, colectomy-free
survival rate was higher with IFX compared to that with CYS (OR
= 1.59, 95% CI: 1.11 −2.29, p = 0.012 for 1 year; OR = 1.57,
95% CI: 1.14–2.18, p= 0.006 for 2 years; and OR= 1.75, 95% CI:
1.08–2.84, p = 0.024 for 3 years), with moderate heterogeneity
across the studies (I2 = 44.3%, p = 0.033; I2 = 0.0%, p =
0.74, and I2 = 42.6%, p = 0.093, respectively) (Figure 5). From
the fourth year of follow-up, no significant difference regarding
the colectomy-free rates was found between the two treatment
groups (Figure 6). At 9 and 10 years of follow-up, only one
small, retrospective study remained in the analysis, where the
colectomy-free survival was higher with IFX compared to that
with CYS (31).
However, separating the data of RCTs revealed that the
significant association can only be seen if observational studies
are included (ORs for observational studies= 1.84, 95%CI: 1.13–
3.01, p= 0.015 in the first year; OR= 1.91, 95%CI: 1.11–3.28, p=
0.020 in the second year; and OR = 2.23, 95% CI: 1.00–4.96, p =
0.049 in the third year; ORs for RCTs = 1.35, 95% CI: 0.90–2.01,
p = 0.143 in the first year; OR = 1.41, 95% CI: 0.94–2.12, p =
0.096 in the second year; and OR = 1.34, 95% CI: 0.89–2.00, p =
0.157 in the third year) (Figure 5). The heterogeneity remained
substantial in the analysis from observational studies but was
negligible if RCTs were included exclusively (in the first year I2
Frontiers in Medicine | www.frontiersin.org 5 January 2020 | Volume 6 | Article 338
Szemes et al. Steroid-Refractory Acute Severe Ulcerative Colitis
TABLE 2 | Modified Newcastle-Ottawa Scale.
Newcastle-Ottawa scale items High-quality items carrying a low risk of
bias (green)
Low-quality items carrying a high (red) or an
unknown (yellow) risk of bias
Selection Item 1: Representativeness of the
initial study population—acute
severe ulcerative colitis (ASUC)
Only patients with ASUC were included Low: beside ASUC moderately severe UC cases
were included.
Unclear: no data on selection process.
Item 2: Representativeness of the
initial study population (ASUC)
Only patients with ASUC were included Low: beside ASUC moderately severe UC cases
were included.
Unclear: no data on selection process.
Item 3: Ascertainment of severity of
ulcerative colitis
ASUCs was defined with objective scores
(e.g., Lichtiger score, Mayo score)
Low: UC was defined with no objective scores
Unclear: no data about objective severity score
Item 4: Demonstration that
outcome of interest was not present
at start of study
The patients had no colectomy before and
were treated with steroid as rescue therapy
Low: patients had any kind of colon resection before
Unclear: no statement.
Comparability Item 5: Study controls for age, sex No significant difference was detected
between patients treated with cyclosporine or
infliximab regarding age.
Low: significant difference was detected between
patients treated with cyclosporine or infliximab
regarding age.
Unclear: no comparison was performed based on age.
Item 6: Study controls for extent of
disease
No significant difference was detected
between patients treated with cyclosporine or
infliximab regarding extent of disease.
Low: significant difference was detected between
patients treated with cyclosporine or infliximab
regarding extent of disease.
Unclear: no comparison was performed based on
extent of disease.
Outcome Item 7: Assessment of outcome Colectomy-free survival rate or numbers of
patients with colectomy were presented at
least 1-year follow-up
Low: colectomy rate only available from the
Kaplan-Meier curve
Unclear: no statement
Item 8: Adequacy of follow-up At least 12 months follow-up period Low: incomplete follow-up with explanations
Unclear: incomplete follow-up without explanation of
the loss.
= 52.6%, p = 0.016 and I2 = 0.0%, p = 0.466, respectively).
TSA indicated that the analysis on colectomy-free survival at 1
year was underpowered, since the monitoring boundaries were
not crossed, and the required information size was not reached
(Figure 1). According to TSA, at least 1,502 patients would be
required for drawing final conclusion while only 416 patients
were included in the current analysis.
Based on our strict and consistent grading, the quality of the
evidence for colectomy-free survival rates at 1, 3, 5, and 10 years
proved to be low for the subgroups of RCTs and very low if
non-randomized studies were included as well (Table 3).
Safety
Seven studies assessed AE (Figure 7) (12, 13, 20, 22, 25, 28, 30).
Sixty-seven (18.1%) AEs were reported with CYS and 72 (18.9%)
with IFX. The pooled OR of AEs was 0.93 (95% CI: 0.45–
1.92, p= 0.847), demonstrating no significant difference between
groups (Figure 7).
The cumulative Z-curve of the risk of AE during TSA reached
but not crossed the conventional boundary (Figure 2). The
number of participants included (n = 385) did not reach the
required information size (n= 749), the cumulative Z-curve does
not cross the monitoring boundary either.
Eight studies reported on SAE, such as opportunistic
infections, sepsis, anaphylactic reaction and hepato- and
nephrotoxicity (Figure 7) (12, 13, 19, 21, 24, 26–28). One
hundred and three (15.5%) SAEs were reported with CYS and
72 (15.3%) with IFX. Rate of SAE was not elevated with IFX
compared to that with CYS (OR = 1.27, 95% CI: 0.86–1.89, p =
0.236); although in the subgroup analysis of observational studies
(21, 24, 26–28), IFX was associated with a higher SAE rate (OR
= 1.80, 95% CI: 1.17–2.79, p = 0.008). However, in the three
RCTs (13, 18, 19), no statistically significant difference could be
detected between the two groups (OR= 0.81, 95% CI: 0.47–1.41,
p= 0.461), data proved to be homogeneous (I2= 0.0%, p= 0.712;
I2 = 0.0%, p= 0.781, and I2 = 7.2%, p= 0.374 for observational
and randomized studies and overall, respectively).
TSA of SAE showed that the number of patients in the
analysis of RCTs did not reach the required information size and
the cumulative Z-curve did not cross the monitoring boundary
(Figure 3).
There was also no significant difference between treatment
groups regarding mortality (OR: 0.79, 95% CI: 0.26–2.38, p =
0.678; I2 = 0.0%, p= 0.411) (Figure 7) (13, 18, 19, 27, 28).
The GRADE assessment of safety outcomes (AE, SAE, and
mortality) showed low quality of evidence for the analyses
of RCTs and very low quality of evidence for that of non-
randomized studies (Table 3).
Risk of Bias Assessment
Assessments of the risk of bias of the included studies are shown
in Figure 8. In the observational studies, the representativeness
of the exposed and the selection of the non-exposed cohort was
judged to be at high risk in multiple studies (23, 28, 30). In
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FIGURE 1 | Results of the trial sequential analysis of the risks of 1 year colectomy-free rate. The required sample size of 1,502 patients was estimated using α = 0.05
(two-sided) and ß = 0.02 (power of 80%). Crossing of the constructed cumulative Z-curves (blue) and the two-sided Z = 1.96 provides a traditionally significant result.
To obtain reliable evidence, crossing of the trial sequential monitoring boundaries (red) is needed. In the case of 1 year colectomy-free rate outcome, the cumulative
Z-curve (blue) did not crossed the conventional boundary and neither the trial sequential monitoring boundary nor the required sample size line was surpassed.
the studies of Daperno, Protic, and Radojcic, no comparison
was performed between groups regarding age, sex, and extent of
disease (21, 28, 29).
Among the RCTs, the studies of Williams and Laharie
carried the lowest risk of bias (13, 18). As they were open
trials, participants and personnel were not blinded; however, in
the study of Williams, outcome assessment remained blinded.
Because the study of Scimeca et al., was only published in a
conference abstract form, almost all domains were judged as
carrying “unclear” risk of bias (19).
DISCUSSION
Summary of Main Findings
ASUC is a medical emergency and should be managed in high-
volume tertiary centers with a multidisciplinary approach. In
patients failing to respond to parenteral corticosteroids, medical
rescue therapy including CYS or IFX is needed. Recently, a meta-
analysis has covered the short-term efficacy of the two drugs in
treatment response and 12 months colectomy rates but failed to
discuss long-term outcomes (14).
In our meta-analysis, we collected RCTs and observational
studies to perform long-term statistics focusing on colectomy-
free survival rates and drug safety. Our combined data from
all the studies showed that there was a significantly higher
colectomy-free survival rate with IFX compared to that with CYS.
This difference was only seen within the first 3 years after rescue
therapy was initiated and it disappeared after the fourth year
of follow-up. Additionally, we performed a subgroup analysis
by study design to reveal selection bias when comparing RCTs
and observational studies. Higher colectomy-free survival was
found in observational studies with IFX but not in RCTs. It
should be noted that the level of heterogeneity was moderate to
substantial in the analysis from observational studies whilst data
from RCTs were homogenous. When evaluating safety outcomes,
no significant difference was detected between CYS and IFX
treatment groups regarding AE, SAE, and mortality. The neutral
association calculated from RCTs proved to be underpowered
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FIGURE 2 | Results of the trial sequential analysis of the risks of adverse events. The required sample size was calculated with α = 0.05 (two-sided) and ß = 0.02
(power of 80%). Although cumulative Z-curve (blue) reached the conventional boundary, it did not cross through. Number of participants (385) did not reach the
information size (749) and the cumulative Z-curve does not cross the monitoring boundary either.
FIGURE 3 | Results of the trial sequential analysis of the risks of serious adverse events. The required sample size was calculated using α = 0.05 (two-sided) and
ß = 0.02 (power of 80%). The cumulative Z-curve (blue) did not cross the monitoring boundary (red) and not reached the required information size (4,325 patients).
There is insufficient information about the evidence of significance.
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FIGURE 4 | PRISMA flowchart.
(indicated by TSA) and therefore insufficient to draw a final
conclusion (36).
During ASUC treatment, early identification of steroid
refractoriness and early introduction of rescue treatments are
crucial to avoid morbidity and mortality. A variety of risk
prediction tools have been developed to identify patients with
ASUC being suitable for second-line medical therapy, these tools
are used in clinical practice (such as the Oxford criteria and
the Ho index) (53, 54). In a retrospective study, older age,
severe endoscopic lesions, high CRP, low albumin levels and low
serum IFX levels were identified as predictors of IFX failure in
ASUC (30). Due to increased intestinal loss of IFX in ASUC, the
serum IFX levels could be decreased; therefore, a modified IFX
induction strategy can be considered (55). However, the results
of other studies have opposed this association. Dose optimization
based on IFX drug level monitoring may result in better patient
outcomes (56, 57). In a retrospective study and meta-analysis, no
association was found between accelerated IFX induction therapy
and lower rates of colectomy in patients with ASUC, compared
to standard induction therapy (58). The benefit of intensified
induction regimen, i.e., shorter dosing intervals and/or higher
doses of IFX is still not proven.
Limitations and Strengths
However, we are aware that our findings suffer from several
limitations. First, most of the studies were non-randomized,
retrospective studies, and the number of RCTs was low. Second,
the use of maintenance therapy after the initial response was
not uniform in all studies and must have contributed to the
variation in the long-term outcomes. Third, the definitions of
AE and SAE were often mixed together and were unclear in
the reports; therefore, an internationally accepted guide has been
adopted (17). Fourth, in two RCTs (13, 18), there is switch
reported in some cases between CYS and IFX or IFX and CYS
as third-line rescue therapy. The switch was necessary to avoid
colectomy and achieve clinical remission. However, this can
cause a difficulty defining the effect of the drug and may affect
the long-term outcome.
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FIGURE 5 | Odds ratios of colectomy-free survival with infliximab (vs. cyclosporine) in the first, second, and third year in steroid-refractory acute severe ulcerative
colitis.
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FIGURE 6 | Odds ratios of colectomy-free survival with infliximab (vs. cyclosporine) between the fourth and tenth year in steroid-refractory acute severe ulcerative
colitis.
We deviated from the PROSPERO protocol regarding
an important point. Originally, the primary outcome
was planned to be the 5 years colectomy-free survival.
However, we thought that investigating the same outcome
at multiple time points may improve the clinical yield of
the results.
Last, conference abstracts with limited information were
also included in the meta-analysis, containing a high amount
of unclear information and an increasing possibility of
risk of bias.
There are several strengths of our meta-analysis that worth
being highlighted. Altogether, a high number of patients
with ASUC was investigated. Our meta-analysis is the first
reporting more than 1 year colectomy free-survival rates
with a high number of studies providing even seven or
10 years of colectomy-free survival data. Another strength
of our meta-analysis is that the certainty of the evidence
was examined for all outcomes according to the GRADE
approach (37). Moreover, TSA was used to test whether
the analyses are sufficiently powered; therefore, can be
considered conclusive.
CONCLUSIONS
In summary, our meta-analysis has shown that there is no
definitive evidence for any difference regarding long-term
efficacy and safety between CYS and IFX in patients with
steroid-refractory ASUC based on RCTs. Considering second-
line treatment options in ASUC, the choice of drug depends
on several factors other than efficacy and safety. Since the
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TABLE 3 | Investigation of quality of the evidence for all included outcomes (GRADE).
Measured outcomes Study design Risk of bias Inconsistency Indirectness Imprecision Publication bias Other (upgrading
factors*)
Quality of the
evidence
Colectomy-free rate in
the first year
Non-randomized studies (n
= 12) (starts as low quality)
Data are from
studies at low risk of
bias
Low heterogeneity
(I2 = 0%)
Evidence that the
studies found is no
more restrictive then
our PICO
Small sample sizes (<400
patients) (−1)
All results come from
small studies (−1)
None Very low
•◦◦◦
RCTs (n = 3) (starts as high
quality)
Data are from
studies at
low/unclear risk of
bias
Low heterogeneity
(I2 = 0%)
Evidence that the
studies found is no
more restrictive then
our PICO
Small sample sizes (<400
patients) (−1)
All results come from
small studies (−1)
None Low
••◦◦
Colectomy-free rate in
the third year
Non-randomized studies (n
= 6) (starts as low quality)
Data are from
studies at low risk of
bias
Moderate
heterogeneity (I2 >
60%) (−1)
Evidence that the
studies found is no
more restrictive then
our PICO
Small sample sizes (<400
patients) (−1)
All results come from
small studies (−1)
None Very low
•◦◦◦
RCTs (n = 2) (starts as high
quality)
Data are from
studies at low risk of
bias
Low heterogeneity
(I2 = 0%)
Evidence that the
studies found is no
more restrictive then
our PICO
Small sample sizes (<400
patients) (−1)
All results come from
small studies (−1)
None Low
••◦◦
Colectomy-free rate in
the fifth year
Non-randomized studies (n
= 4) (starts as low quality)
Data are from
studies at low risk of
bias
Moderate
heterogeneity (I2 >
60%) (−1)
Evidence that the
studies found is no
more restrictive then
our PICO
Small sample sizes (<400
patients) (−1)
All results come from
small studies (−1)
None Very low
•◦◦◦
RCTs (n = 1) (starts as high
quality)
Data are from
studies at low risk of
bias
Evidence that the
studies found is no
more restrictive then
our PICO
Small sample sizes (<400
patients) (−1)
All results come from
small studies (−1)
None Low
••◦◦
Colectomy-free rate in
the tenth year
Non-randomized studies (n
= 1) (starts as low quality)
Data are from
studies at low risk of
bias
NA Evidence that the
studies found is no
more restrictive then
our PICO
Small sample sizes (<400
patients) (−1)
All results come from
small studies (−1)
None Very low
•◦◦◦
(No RCT in the tenth year) NA NA NA NA NA NA NA
Adverse events Non-randomized studies (n
= 5) (starts as low quality)
Data are from
studies at low/high
risk of bias (−1)
Moderate
heterogeneity (I2 >
60%) (−1)
Evidence that the
studies found is no
more restrictive then
our PICO
Small sample sizes (<400
patients) (−1)
All results come from
small studies (−1)
None Very low
•◦◦◦
RCTs (n = 2) (starts as high
quality)
Data are from
studies at low risk of
bias
Low heterogeneity
(I2 = 0%)
Evidence that the
studies found is no
more restrictive then
our PICO
Small sample sizes (<400
patients) (−1)
All results come from
small studies (−1)
None Low
••◦◦
Serious adverse events Non-randomized studies (n
= 5) (starts as low quality)
Data are from
studies at
low/unclear risk of
bias (−1)
Low heterogeneity
(I2 = 0%)
Evidence that the
studies found is no
more restrictive then
our PICO
Small sample sizes (<400
patients) (−1)
All results come from
small studies (−1)
None Very low
•◦◦◦
RCTs (n = 3) (starts as high
quality)
Data are from
studies at
low/unclear risk of
bias (−1)
Low heterogeneity
(I2 = 0%)
Evidence that the
studies found is no
more restrictive then
our PICO
Small sample sizes (<400
patients) (−1)
All results come from
small studies (−1)
None Low
••◦◦
Mortality Non-randomized studies (n
= 2) (starts as low quality)
Data are from
studies at low/high
risk of bias (−1)
Low heterogeneity
(I2 = 0%)
Evidence that the
studies found is no
more restrictive then
our PICO
Small sample sizes (<400
patients) (−1)
All results come from
small studies (−1)
None Very low
•◦◦◦
RCTs (n = 3) (starts as high
quality)
Data are from
studies at
low/unclear risk of
bias (−1)
Low heterogeneity
(I2 >40%)
Evidence that the
studies found is no
more restrictive then
our PICO
Small sample sizes (<400
patients) (−1)
All results come from
small studies (−1)
None Low
••◦◦
*Including large effect, dose response, no plausible confounding factors, NA, non-applicable.
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FIGURE 7 | Odds ratios of studies evaluating adverse events, serious adverse events, and mortality during infliximab treatment compared to the cyclosporine group in
steroid-refractory acute severe ulcerative colitis.
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FIGURE 8 | Risk of bias in (A) RCTs and in (B) non-randomized studies.
introduction of IFX, as rescue therapy for ASUC and a proxy
for CYS, the length of hospital stay and in-hospital costs have
been reduced significantly (59). On the other hand, the total
costs up to 3 months after initiation of rescue therapy were
significantly higher in the IFX group (59). However, since 2013
lower-cost IFX biosimilars are available, which may result in
large cost savings in the future. In addition to safety and
efficacy, other components of evidence-based medicine, such as
the experience of treating physicians and patient preferences,
should also be highlighted. In thiopurine-naïve patients, CYS can
be preferred as a bridge to thiopurine maintenance treatment.
IFX is a reasonable option for patients who have previously
failed thiopurine maintenance therapy. Results of TSA and the
lack of high-quality evidence in our meta-analysis highlight that
further large RCTs are warranted to decide which therapy is the
preferable rescue therapy in ASUC.
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